Rosa Rossling1, Rene Dittrich1, Emily Decelle2, Chin-Lee Wu2, W Scott McDougal2, Leo L. Cheng2
1Charit Universittsmedizin, Berlin, Germany; 2Massachusetts General Hospital, Boston, MA, United States
Implementation of PSA testing has increased the number of early diagnosed cases of prostate cancer. This shift in diagnosis necessitates the evolution of pathology and other biomolecular markers to identify and categorize early stages of the disease. In previous studies, citrate has been identified as a potential marker for malignancy and aggressiveness. Here we correlate citrate levels with PSA velocity, PSA density, percent free PSA, which we are using as surrogate markers for PCa growth and aggressiveness.